latest news releases from the newsroom
Avigen Receives Approval to Initiate AV650 Phase II Clinical Development
ALAMEDA, Calif., March 14, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN) a biopharmaceutical company developing innovative therapies for the treatment of neurological conditions, today announced it was given approval from the U.S. Food and Drug Administration to commence Phase II clinical development of AV650 (tolperisone). AV650 is a New Chemical Entity (NCE) in the United States. Tolperisone is approved in several EU member countries for the treatment of spasticity and muscle spasms. Avigen's initial Phase II trial will assess the safety, tolerability, and initial efficacy, as well as AV650's lack of sedation, in spinal cord injury patients suffering from spasticity. This study will be a multi-center, double-blind, placebo-controlled trial and will explore doses up to the EU approved dose of 450 mg per day.
China Career Builder Corp.
China Career Builder Corp. Announces Plan to Acquire Asian Career Company Ltd. of Hong Kong
HONG KONG, March 14, 2007 (PRIME NEWSWIRE) -- China Career Builder Corp., (Pink Sheets:CCBX) a Delaware Corporation, is focused on outsourcing human resource services and staffing in Hong Kong, China. The company is pleased to announce a plan to acquire Asian Career Company of Hong Kong. The company is expected to complete the transaction in the next Two (2) to Four (4) weeks. All additional information will be available upon finalization of the acquisition. The company will make further announcements in coming weeks.
Medicis Pharmaceutical Corporation
Medicis Declares Cash Dividend
SCOTTSDALE, Ariz., March 14, 2007 (PRIME NEWSWIRE) -- Medicis (NYSE:MRX) today announced that its Board of Directors declared a quarter-end cash dividend of $0.03 per issued and outstanding share of its Common Stock payable on April 30, 2007, to stockholders of record at the close of business on April 2, 2007.